M&T Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

M&T Bank’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$438K	Buy	814 +232	+40%	+$119K	﹤0.01%	1274
2026 Q1	$305K	Sell	582 -47	-7%	-$22.5K	﹤0.01%	1373
2025 Q4	$366K	Buy	+629	New	+$321K	﹤0.01%	1277

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

M&T Bank's MDGL Position: Q2 2026 in Review

M&T Bank increased its Madrigal Pharmaceuticals (MDGL) stake by 40% in Q2 2026, buying an estimated $119K and bringing the position to 814 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

M&T Bank first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

M&T Bank held 814 shares of Madrigal Pharmaceuticals worth $438K as of Q2 2026.
M&T Bank bought 232 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $119K.
Madrigal Pharmaceuticals made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1274 holding.
M&T Bank first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.